ONCONETIX INC

ONCONASDAQ

🏆 #4053 by market capEarnings Aug 17US Equity

$839.12▲ $55.05 (+6.56%)

Simulated price

1h—

24h▲ 6.6%

7d—

14d—

30d—

1y—

🏦Market Cap

$3M

Small Cap

📈Revenue Growth (YoY)

-67.7%

Declining

📊Gross Margin

79.6%

High

💵FCF Margin

-1333.0%

Thin

⚖️P/S Ratio

4.7x

Fair

Otter Score

Fair

No chart data available for ONCO.

Trading Snapshot

Day Range: $827.36 – $855.09
52-Week Range: $0.67 – $209.50
Volume: $2.98B
Avg Volume: $2.52B
Shares Outstanding: 3.6M
Next Earnings: Sep 11, 2026

Fundamentals Snapshot

Annual Revenue: $815,371
Last Q Revenue: $21,457
P/E Ratio: -0.1
P/S Ratio: 4.7x
EPS (TTM): $-15.44
Dividend Yield: 0.00%

Why Investors Own ONCO

✓High-growth profile — revenue up +13.3% YoY with expanding US Equity exposure.
✓Healthy economics — 78% gross margin and 8% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$815,371▲ +10.1% YoY

Gross Margin (TTM)

77.5%▲ +0.5% YoY

Operating Income (TTM)

$87,245▲ +10.1% YoY

Free Cash Flow (TTM)

$65,230▲ +10.1% YoY

About ONCONETIX INC

Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH). In its development pipeline, Onconetix is advancing a Streptococcus pneumoniae vaccine candidate, designed to prevent infectious middle ear infections in children and pneumonia in the elderly. Additionally, they are working on a universal influenza vaccine intended to provide comprehensive protection against all aggressive strains of the flu virus. Furthermore, Onconetix holds a license for an advanced norovirus S&P nanoparticle virus-like particle (VLP) vaccine platform from Cincinnati Children's. This adaptable platform is being leveraged to create vaccines for various infectious diseases, such as Marburg and monkeypox, among others. Established in 2018, the company was previously known as Blue Water Biotech, Inc., before changing its name to Onconetix, Inc. in December 2023. Its corporate headquarters are located in Cincinnati, Ohio.

🦦